FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Presents Device Review Assessment

[ Price : $8.95]

Federal Register Notice: FDA reveals high priority recommendations from an independent assessment of the device review process.

Nuvilex Plans Late-Phase Clinical Trials in Pancreatic Cancer

[ Price : $8.95]

Nuvilex plans a late-phase clinical trial comparing its investigational treatment with gemcitabine in patients with advanced, inop...

Drug Makers with Advanced Facilities See Fewer Inspections: Woodcock

[ Price : $8.95]

CDER director Janet Woodcock says FDA inspectors have shifted more focus to drug manufacturers that have operations that are antiq...

John Taylor Leaving FDA Again

[ Price : $8.95]

FDA counselor to the commissioner and Global Regulatory Operations and Policy (GO) acting deputy commissioner John M. Taylor resig...

State AGs Want Zohydro ER Pulled or Reformulated

[ Price : $8.95]

Attorneys general from 29 states ask FDA to reconsider its approval of Zogenix Zohydro ER or order it to be reformulated to be abu...

FDA Can Improve Medical Device Submission Process: Study

[ Price : $8.95]

Consultants Booz Allen Hamilton recommend four steps FDA could take to improve the medical device submission review process under ...

CDRH, ORA Compliance Improvement Pilot Program

[ Price : $8.95]

Additionally, FDA says it will expedite export certificate requests and prioritize device and pre-amendment determination requests...

FDA Panel Backs Stallergenes Allergy Drug

[ Price : $8.95]

FDAs Allergenic Products Advisory Committee votes 9 to 1 that available data support approval of a BLA for Oralair, indicated for ...

Group Pens Open Letter to Hamburg on Vascepa Protocol Change

[ Price : $8.95]

The EPA Drug Initiative pens an open letter to FDA commissioner Margaret Hamburg asking her to intervene and reverse a recent CDER...

Social Media Posts Should Include Risk Info

[ Price : $8.95]

A recent blog post says companies should not give drug product information in social media without including the drugs pertinent r...